How do MK-801 and risperidone modulate the proteome of human oligodendrocytes?

Abstract

Schizophrenia is a complex neuropsychiatric disorder developed by genetic and environmental factors. The treatment is based on antipsychotics, such as risperidone. Some of illness symptoms has been mimic by MK-801, a non-competitive antagonist of glutamate NMDA receptor. Proteome evidences have been shown disturbances in oligodendrocytes metabolism of schizophrenia patients, mainly in energy metabolism. The aim of this study is to characterize the proteome of a human oligodendrocyte cell line treated with MK-801, risperidone and the co-treatment, in order to shed light about the interactions between schizophrenia and the antipsychotic drug risperidone.